Literature DB >> 33417227

Phosphoenolpyruvate Carboxykinase (PCK) in the Brain Gluconeogenic Pathway Contributes to Oxidative and Lactic Injury After Stroke.

Xiaokun Geng1,2,3, Jiamei Shen4, Fengwu Li4, James Yip5, Longfei Guan4,6,7, Gary Rajah6,8, Changya Peng6, Donald DeGracia9,10, Yuchuan Ding11,12.   

Abstract

To demonstrate the role of the rate-limiting and ATP-dependent gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PCK) in oxidative and lactic stress and the effect of phenothiazine on PCK after stroke, a total of 168 adult male Sprague Dawley rats (3 months old, 280-300 g) underwent 2-h intraluminal middle cerebral artery occlusion (MCAO) and reperfusion for 6, 24, 48 h, or 7 days. Phenothiazine (chlorpromazine and promethazine (C+P)) (8 mg/kg) and 3-mercaptopicolinic acid (3-MPA, a PCK inhibitor, 100 μM) were administered at reperfusion onset. The effects of phosphoenolpyruvate, 3-MPA, or PCK knockdown were studied in neuronal cultures subjected to oxygen/glucose deprivation. Reactive oxygen species, lactate, phosphoenolpyruvate (PEP; a gluconeogenic product), mRNA, and protein of total PCK, PCK-1, and PCK-2 increased after MCAO and oxygen-glucose deprivation (OGD). Oxaloacetate (a gluconeogenic substrate) decreased, while PEP and glucose were increased, suggesting reactive gluconeogenesis. These changes were attenuated by phenothiazine, 3-MPA, or PCK shRNA. PCK-1 and -2 existed primarily in neurons, while the effects of ischemic stroke on the PCK expression were seen predominately in astrocytes. Thus, phenothiazine reduced infarction and oxidative/lactic stress by inhibiting PCKs, leading to functional recovery.

Entities:  

Keywords:  Gluconeogenesis; Ischemia/reperfusion; Neuroprotection; Phenothiazine (promethazine, chlorpromazine, C+P)

Year:  2021        PMID: 33417227     DOI: 10.1007/s12035-020-02251-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  31 in total

Review 1.  Glucose modulation of ischemic brain injury: review and clinical recommendations.

Authors:  C T Wass; W L Lanier
Journal:  Mayo Clin Proc       Date:  1996-08       Impact factor: 7.616

2.  Macrophages with a deletion of the phosphoenolpyruvate carboxykinase 1 (Pck1) gene have a more proinflammatory phenotype.

Authors:  Chih-Wei Ko; Daniel Counihan; Jing Wu; Maria Hatzoglou; Michelle A Puchowicz; Colleen M Croniger
Journal:  J Biol Chem       Date:  2018-01-09       Impact factor: 5.157

Review 3.  Management of hyperglycemia in acute stroke: how, when, and for whom?

Authors:  Michael T McCormick; Keith W Muir; Christopher S Gray; Matthew R Walters
Journal:  Stroke       Date:  2008-04-24       Impact factor: 7.914

4.  Neuroprotection by Chlorpromazine and Promethazine in Severe Transient and Permanent Ischemic Stroke.

Authors:  Xiaokun Geng; Fengwu Li; James Yip; Changya Peng; Omar Elmadhoun; Jiamei Shen; Xunming Ji; Yuchuan Ding
Journal:  Mol Neurobiol       Date:  2016-11-28       Impact factor: 5.590

Review 5.  Hyperglycemia in stroke and possible treatments.

Authors:  William A Li; Shannon Moore-Langston; Tia Chakraborty; Jose A Rafols; Alana C Conti; Yuchuan Ding
Journal:  Neurol Res       Date:  2013-04-23       Impact factor: 2.448

Review 6.  Opposing effects of glucose on stroke and reperfusion injury: acidosis, oxidative stress, and energy metabolism.

Authors:  Nathaniel M Robbins; Raymond A Swanson
Journal:  Stroke       Date:  2014-04-17       Impact factor: 7.914

Review 7.  Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation.

Authors:  Ángel Chamorro; Ulrich Dirnagl; Xabier Urra; Anna M Planas
Journal:  Lancet Neurol       Date:  2016-05-11       Impact factor: 44.182

Review 8.  Cerebral Gluconeogenesis and Diseases.

Authors:  James Yip; Xiaokun Geng; Jiamei Shen; Yuchuan Ding
Journal:  Front Pharmacol       Date:  2017-01-04       Impact factor: 5.810

9.  Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors.

Authors:  Pei-Yi Chu; Shih Sheng Jiang; Yan-Shen Shan; Wen-Chun Hung; Ming-Huang Chen; Hui-You Lin; Yu-Lin Chen; Hui-Jen Tsai; Li-Tzong Chen
Journal:  Oncotarget       Date:  2017-10-09

Review 10.  The cerebral circulation and cerebrovascular disease III: Stroke.

Authors:  Ankush Chandra; Christopher R Stone; Xiangnan Du; William A Li; Mitchell Huber; Richard Bremer; Xiaokun Geng; Yuchuan Ding
Journal:  Brain Circ       Date:  2017-07-18
View more
  5 in total

1.  Neuroprotective Effects of Pharmacological Hypothermia on Hyperglycolysis and Gluconeogenesis in Rats after Ischemic Stroke.

Authors:  Longfei Guan; Hangil Lee; Xiaokun Geng; Fengwu Li; Jiamei Shen; Yu Ji; Changya Peng; Huishan Du; Yuchuan Ding
Journal:  Biomolecules       Date:  2022-06-19

Review 2.  Role of Forkhead Box Protein O1 (FoxO1) in Stroke: A Literature Review.

Authors:  Sichao Guo; Ruchi Mangal; Chaitu Dandu; Xiaokun Geng; Yuchuan Ding
Journal:  Aging Dis       Date:  2022-04-01       Impact factor: 6.745

3.  Chicoric Acid Prevents Neuroinflammation and Neurodegeneration in a Mouse Parkinson's Disease Model: Immune Response and Transcriptome Profile of the Spleen and Colon.

Authors:  Ning Wang; Rui Li; Bainian Feng; Yuliang Cheng; Yahui Guo; He Qian
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

4.  Human iPSC-derived cerebral organoids model features of Leigh syndrome and reveal abnormal corticogenesis.

Authors:  Alejandra I Romero-Morales; Gabriella L Robertson; Anuj Rastogi; Megan L Rasmussen; Hoor Temuri; Gregory Scott McElroy; Ram Prosad Chakrabarty; Lawrence Hsu; Paula M Almonacid; Bryan A Millis; Navdeep S Chandel; Jean-Philippe Cartailler; Vivian Gama
Journal:  Development       Date:  2022-07-06       Impact factor: 6.862

Review 5.  Perspectives on benefit of early and prereperfusion hypothermia by pharmacological approach in stroke.

Authors:  Fengwu Li; Jie Gao; Wesley Kohls; Xiaokun Geng; Yuchuan Ding
Journal:  Brain Circ       Date:  2022-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.